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ABSTRACT 
Objectives 
Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple 
organs. A validated instrument is essential to quantify damage in individual patients, and to compare 
disease outcomes in clinical studies. Curently, there is no such tool. Our objective was to develop a 
common autoinflammatory disease damage index (ADDI) for Familial Mediterranean Fever (FMF), 
Cryopyrin Associated Periodic Syndromes (CAPS), Tumour Necrosis Factor Receptor Associated 
Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD).  
 
Methods  
We developed the ADDI by consensus building. The top 40 enrollers of patients in the Eurofever 
registry and nine experts from the Americas participated in multiple rounds of online surveys to 
select items and definitions. Further, 22 (parents of) patients rated damage items, and suggested 
new items. A consensus meeting was held to refine the items and definitions, which were then 
formally weighted in a scoring system derived using decision-making software, known as 1000minds.  
 
Results 
More than 80% of the experts and patients completed the online surveys. The preliminary ADDI 
contains eighteen items, categorized in the following eight organ systems: reproductive, 
renal/amyloidosis, developmental, serosal, neurological, ears, ocular and musculoskeletal damage 
The categories renal/amyloidosis and neurological damage were assigned the highest number of 
points, serosal damage the lowest number of points. The involvement of (parents of) patients 
resulted in the inclusion of e.g. chronic musculoskeletal pain. 
 
Conclusions 
An instrument to measure damage caused by autoinflammatory diseases is developed based on 
consensus building. Patients fulfilled a significant role in this process. 
 
INTRODUCTION 
 
Autoinflammatory diseases (AID) cover a spectrum of diseases, which lead to chronic or recurrent 
inflammation caused by activation of the innate immune system, typically in the absence of high-titre 
autoantibodies.[1] Over recent decades a number of autoinflammatory diseases has been 
recognized, genetic defects identified and the pathogenic mechanisms elucidated.[2] 
The four most common monogenic AID are Cryopyrin-Associated Periodic Syndromes (CAPS), Familial 
Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD) and Tumour necrosis factor 
Receptor-Associated Periodic fever Syndrome (TRAPS). In these hereditary AID chronic and recurrent 
inflammation can lead to both acute disease, and chronic irreversible damage.[3]  
Targeted therapy for many AID has become available with blocking interleukin-1 beta (IL-1β) 
signalling and/or tumour necrosis factor (TNF) signalling, and for many patients, control of active 
inflammation can be achieved. However, organ damage may have accrued in the pre-diagnostic or 
pre-therapeutic phase of the illness, particularly for those with delayed diagnosis; and the control of 
disease activity may not be complete in every patient.[4] Therefore many patients may still develop 
chronic damage from AID. This is especially true for patients for whom effective therapy is 
unaffordable or unavailable, since many of these biological treatments are very expensive. To-date 
there is no validated means of assessing the long-term burden of AID available.  
Currently, there is a patient-reported validated tool to quantify acute inflammatory activity in 
inherited periodic fevers (the autoinflammatory disease activity index, AIDAI); and there is a disease 
severity index for FMF, but by definition these do not assess long-term damage such as hearing loss, 
blindness, and renal failure.[5-8] Damage indices for other rheumatic diseases such as vasculitis, 
systemic lupus erythematosus, dermatomyositis and juvenile idiopathic arthritis have already been 
developed and validated.[9-13]  
When devising new damage assessment tools therapeutic toxicity must also be considered, for 
example chronic glucocorticoid toxicity which can lead to cataract, growth failure and other 
damaging side-effects. Thus, a comprehensive damage outcome measurement tool for AID must 
capture chronic and potentially irreversible disorders of structure and function that have risen in 
patients as a result of their autoinflammatory disease and/or its treatment. The creation of such an 
index was a stated aim of the European Union ERANET-PRIOMEDCHILD RaDiCEA Project No. 40-
41800-98-007. 
The main intended purpose of the autoinflammatory disease damage index (ADDI) is to analyse the 
outcome of patient groups, for example to capture and record damage in clinical trials. In addition, it 
may serve as an aid to physicians in assessing the needs of their patients, for example when trying to 
secure funding for biologic therapies. The proposed ADDI will be designed for use in the four more 
commonly encountered monogenic AID: FMF, CAPS, TRAPS and MKD. The ADDI will ideally be used 
as one of a set of measures to capture the disease burden for affected patients, in addition to 
validated measures of disease activity, disease severity and quality of life. 
METHODS  
This study was approved by The Medical Ethical Committee of the University Medical Centre Utrecht. 
We developed the ADDI by consensus building, with online surveys based on the Delphi method 
followed by a face-to-face consensus meeting. The Delphi method is a widely accepted and 
commonly used method to structurally reach consensus in a group of experts.[14]  
 
Selection of experts and patients 
The top 40 enrollers to the Eurofever Registry, a European research database for patients with 
AID,[15] were invited to participate as experts; another nine experts who had not participated in the 
European-based Eurofever Registry were recruited from the Americas. Members of this expert group 
participated in multiple online surveys, and were invited for the face-to-face consensus meeting. In 
close collaboration with the Autoinflammatory Alliance.[16] We also invited 22 patients and parents 
of patients with FMF, CAPS, TRAPS or MKD to participate in an online survey, and an additional three 
patients to participate in the weighting of items, using the 1000minds decision-making software (see 
below, step 4). Inclusion criteria for selection were: 1. English speaking patients of 18 years and older 
or parents of a paediatric patient with FMF, MKD, CAPS or TRAPS; and 2. Provision of fully informed 
signed consent to participate in this exercise, separately for both online surveys and interviews.  
 
Step 1: Search for possible damage items 
First, a systematic literature search was performed to establish possible damage items for FMF, MKD, 
CAPS and TRAPS. Inclusion of articles to be considered was based on: 1. all studies and case series 
describing symptoms and complications of more than three patients with FMF, MKD, CAPS and/or 
TRAPS; 2. published in English; and 3. case reports (with three or fewer patients) were included if 
they described significant new damage items. All data on the prevalence of the sequelae were 
extracted. We included all sequelae described in studies with patients with FMF, CAPS, TRAPS and 
MKD which were likely to be caused by chronic inflammation or its treatment, and which persisted 
after resolution of inflammatory episodes.  
 
Secondly, we screened all items scored in the Eurofever Registry to identify new damage items not 
identified from the literature review. Thirdly, we asked patients in the first online survey to propose 
relevant new damage items. We interviewed the patients who gave informed consent for the 
interviews, to try to identify other relevant damage items: we asked them specifically which 
complications/symptoms they most fear, and which symptoms/complications create the greatest 
limitation of daily life. Finally, we asked experts in the first online survey for relevant new damage 
items (see step 2). 
 
Step 2: Multiple rounds of online surveys with experts 
Four rounds of online surveys were performed as a preparation for the consensus meeting. Experts 
scored all potential damage items for inclusion in the index, as well as the definitions and grading of 
items. Experts also suggested new items, combinations of items and new options for 
definitions/grading. If ≥80% of the experts endorsed an item, it was included in the index. If an item 
reached <50% consensus, the item was excluded. In cases were 50 to 80% of the experts favoured 
inclusion, it was reconsidered in the next round. These thresholds were also used for the definitions 
and grading of the items. 
 
Step 3: Face-to-face Consensus meeting 
The 43 experts who completed one or more of the online surveys, as well as the director of the 
Autoinflammatory Alliance as a patient/parent representative, were invited to the consensus 
meeting. The first day, the definition of damage and the inclusion/definitions of the items that did 
not reach consensus in the online surveys were discussed. On day two, all items that reached 
consensus in the online surveys were refined. The results of the online surveys with experts and the 
patient/parent surveys and interviews were presented per item, followed by a maximum of three 
voting rounds and discussion. Items and definitions with 80% consensus or more were included in 
the ADDI. Items with no consensus after three voting rounds were excluded. After the consensus 
meeting we sent a final online survey to all participants, to ask whether they agreed with the items 
including the definitions as proposed at the consensus meeting.  
 
Step 4: Development of a scoring system. 
To assign an appropriate weight to each damage item, we used the 1000minds software in order to 
develop the scoring system of the ADDI.[17] 1000minds is a decision-making program that compares 
two items in order to grade the alternatives using the Potentially All Pairwise RanKings of all possible 
Alternatives (PAPRIKA) method.[18] Briefly, this method provides repeated comparisons between 
two items; the expert or patient chooses which of the two items constitutes the greater burden for 
patients. Each item receives a ‘preference value’ according to the PAPRIKA method, this reflects the 
importance of this item compared to all the other items. Hence, items with the greatest burden got 
the highest preference value and thus received most points in the ADDI. 
 
All experts and the patients were asked to complete 1000minds. We compared the means of the 
patient survey and the expert survey. Differences between the overall mean and the expert mean, as 
well as maximizing the amount of points per category were discussed in a web conference with a 
small group of experts. These experts were from different continents and included both paediatric 
rheumatologists and rheumatologists for adults. 
 
RESULTS 
Identification of damage items from literature search and Eurofever registry  
In the literature searches we found 1712 articles for CAPS, 632 for MKD, 2602 for FMF and 486 for 
TRAPS, after screening for title and abstract 150 articles for CAPS, 87 for MKD, 251 for FMF and 55 
for TRAPS remained. After screening for full text we included 36 articles for CAPS, 9 for MKD, 54 for 
FMF and 8 for TRAPS; in total 49 separate damage items were extracted from these articles (Figure 
1). Eight additional items extracted from the Eurofever Registry were arterial and venous thrombosis, 
arterial aneurysm, large vessel vasculopathy, pulmonary fibrosis, lymphatic dysplasia, camptodactyly 
and kyphoscoliosis. All these items were included in the online surveys with experts and patients. No 
new items were selected from the case reports. 
 
Patient/parent online survey and interviews 
Twenty-two patients/parents of patients provided informed consent to participate in the online 
surveys. Twenty-one patients (95%) completed the online survey and nine of them gave informed 
consent for an interview. For patient characteristics, see Table 1. Patients/parents suggested 
eighteen new damage items, including sexual dysfunction, chronic fatigue and chronic 
musculoskeletal pain (Table 2). The five most important damage items according to patients were AA 
amyloidosis, joint damage, vision loss, neurological damage and renal failure. All these items were 
included in the preliminary ADDI. 
 
Table 1: Patient characteristics 
 First online survey Interviews 1000minds survey 
Total no. of participants, n 21 9 14 
Type of participant, n (%) 
   Patients 
   Parents 
 
12 (57) 
9 (43) 
 
3 (33) 
6 (67) 
 
8 (57) 
6 (43) 
Age, median in years 
(range) 
28 (2-74) 15 (6-68) 29 (6-74) 
Disease, n (%) 
   MKD 
   TRAPS 
   CAPS 
   FMF 
 
6 (29) 
5 (24) 
9 (43) 
1 (5) 
 
1 (11) 
3 (33) 
4 (44) 
1 (11) 
 
3 (21) 
3 (21) 
6 (43) 
2 (14) 
Country of residence, n (%) 
   Australia 
   Canada 
   Switzerland 
   Netherlands 
   United States of America 
   United Kingdom 
 
2 (10) 
1 (5) 
1 (5) 
2 (10) 
15 (71) 
0 (0) 
 
7 (78) 
2 (22) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
1 (7) 
0 (0) 
0 (0) 
2 (14) 
10 (71) 
1 (7) 
 
Expert online surveys  
Forty-nine experts were invited for the online surveys. The median number (range) of included 
patients in the Eurofever registry for the 40 Eurofever experts was 49 (19-194) patients per expert. 
All rounds were completed by more than 80% of the experts. Experts suggested sixteen new damage 
items, including persistent haematuria, chronic fatigue and corneal opacities (Table 2). Eight items 
reached consensus for inclusion in the online surveys. Forty-two items were excluded as <50% of the 
experts voted in favour of the item. Examples were lymphatic dysplasia, sexual dysfunction and 
glomerulonephritis. Sexual dysfunction was excluded, because experts concluded that it would be 
difficult to prove a causal relation with the disease (i.e. whether it can be seen as disease-associated 
damage), moreover it might reflect disease activity rather than damage. Seven items were discussed 
in the consensus meeting as between 50% and 80% of the experts wanted to include the item. Six of 
the fifteen definitions required further discussion in the consensus meeting.  
 
 
 
 
 
Table 2: Items suggested by patients and experts, as an addition to the literature. 
 
Consensus meeting 
On the first day, 31 of the 43 invited participants were able to attend the meeting. The participants 
discussed the items and definitions that did not reach consensus in the online survey. The 
participants excluded neuropathy, muscle weakness and mood disorders. Consensus was reached 
about all definitions that needed reconsideration. On the second day, 29 experts were present and 
refined all items that already reached consensus, including the definitions of these items. In the 
online survey following the consensus meeting, 35 experts agreed with almost all adaptions made in 
the consensus meeting. Only fatigue was finally excluded following this survey.  
 
Most important discussions in the consensus meeting 
Inclusion of infertility and amenorrhea did not reach consensus in the online surveys, but in the 
consensus meeting adult rheumatologists emphasized the great burden for patients caused by 
infertility. After discussion, >80% of the participants agreed on including these items. 
Cognitive impairment was included as an addition to developmental delay in the consensus meeting. 
As there is a variety of rare but severe central nervous system (CNS) complications, the participants 
decided to group all in one item, CNS involvement.  
 
The group decided to replace the item abdominal adhesions with serosal scarring in order to include 
all potential serosal damage, e.g. retroperitoneal fibrosis. Destructive arthritis and joint contractures 
were combined into one inclusive item, joint restriction, as movement limitation was considered the 
most important functional impact of both items.  
 
Chronic headache was excluded, because this item had a significant overlap with elevated 
intracranial pressure. Chronic musculoskeletal pain and fatigue were initially included in the 
consensus meeting because of the important burden for patients, albeit with a lot of discussion. 
Fatigue was later excluded in the final online survey, because the experts agreed that although 
Category Patient suggestions Expert suggestions 
Developmental Learning difficulties  
Speech developmental delay 
Learning disabilities 
Reproductive Amenorrhoea 
Sexual dysfunction 
Amenorrhoea 
 
Neurological Memory problems 
Delayed motor skill development 
Hand coordination problems 
Hemiplegia/quadriplegia 
Mobility impairment 
 
Gastrointestinal Irritable bowel syndrome 
Portal hypertension 
Malabsorption 
Portal hypertension 
Liver steatosis 
Musculoskeletal Craniofacial deformities Facial deformities 
Muscle wasting 
Ocular Corneal haze 
Retinitis pigmentosa 
Corneal opacity 
Retinitis pigmentosa 
Renal  Persistent haematuria 
Other Social problems 
Loss of future perspective 
Chronic fatigue 
Surgeries 
Autonomic dysregulation 
Chronic pain 
Weight gain 
Somatic growth 
Chronic fatigue 
Dysphonia 
 
 
fatigue can hugely impact a patient’s life, it is difficult to assess due to its subjective nature and 
variable relationship with disease activity.  
 
Development of the scoring system  
Thirty-seven experts and fourteen patients completed the 1000minds survey. The means of 
preference values (experts and patients) ranged from 1.5 to 7.5, in which 1.5 reflected the lowest 
and 7.5 the highest burden for patients. Experts and patients generally scored similar on the 
preference values (Figure 2). A preliminary scoring system based on these preference values was 
presented to a panel of seven representative experts and discussed in a conference call. All items 
with a mean preference value of <3.5 received one point, 3.5 to 5.5 received two points (with the 
exception of serosal scarring which received one point) and of >5.5 three points. Serosal scarring 
received one point; the experts agreed in the conference call that the consequences are less severe 
in comparison to other items receiving two points. Further, a maximum of points per category was 
defined in order to prevent double scoring of identical items. Renal/amyloidosis received a maximum 
amount of six points, as amyloidosis often leads to renal damage. Also the neurological and 
musculoskeletal categories received a decreased maximum of points because of the overlap of the 
items.  
Preliminary ADDI 
Table 3: preliminary ADDI including glossary of terms. 
Preliminary ADDI 
 
Definition of damage: Damage is defined as persistent or irreversible change in structure or function, which 
is present for at least 6 months. Damage items should not be scored if they are attributed to ongoing disease 
activity. Damage may be the result of prior disease activity, complications of therapy or co-morbid 
conditions that developed after the onset of autoinflammatory disease signs and symptoms. If damage has 
been present for longer than 6 months, but later resolves, it should still be scored in order to capture the 
damage that was present in the individual for that time period. 
Damage item Grading Points 
Reproductive                          Max. 3 
Sub/infertility   2 
Amenorrhea   1 
Renal/amyloidosis Max. 6 
Amyloidosis                                            Limited amyloidosis 
Extensive amyloidosis 
2 
3 
Proteinuria   1 
Renal insufficiency  Moderate renal insufficiency 
Severe renal insufficiency 
2 
3 
Developmental Max. 3 
Growth failure   2 
Puberty delay   1 
Serosal Max. 1 
Serosal scarring   1 
Neurological Max. 6 
Developmental delay 1  2 
Cognitive impairment   3 
Elevated intracranial pressure   2 
Central nervous system 
involvement.  
 3 
Ears  Max. 2 
Hearing loss  Moderate hearing loss of better ear 
Severe hearing loss of better ear 
1 
2 
Ocular Max. 3 
Ocular involvement  Mild ocular involvement of better eye 
Moderate ocular involvement of better eye 
Severe moderate ocular involvement of 
better eye 
1 
2 
 
3 
Musculoskeletal Max. 4 
Joint restriction   2 
Bone deformity  2 
Osteoporosis   1 
Musculoskeletal pain   1 
Glossary of terms 
Infertility: A disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 
12 months or more of regular unprotected sexual intercourse, not due to known disorders in the unaffected 
partner.  
Amenorrhea: Primary amenorrhea: absence of menarche at the age of 16 years or absence of menarche 5 
years after thelarche in a female. Secondary amenorrhea: absence of the menses for six consecutive months 
or more, in a female who previously had menstrual cycles. 
Limited amyloidosis: Symptomatic amyloidosis affecting one organ and confirmed by examination of tissue 
sections by Congo red dye or SAP scintigraphy. 
Extensive amyloidosis: Symptomatic amyloidosis affecting more than one organ and confirmed by 
examination of tissue sections by Congo red dye or SAP scintigraphy. 
Proteinuria: Persistent urinary protein to creatinine ratio of >20mg/mmol in the first morning void; and/or a 
daily protein excretion of > 0.3 g/24 hours, or urine albumin to creatinine ratio of > 15 mg/mmol. 
Moderate renal insufficiency: Glomerular filtration rate (GFR) between 15-60 ml/min/1,73m2. 
Severe renal insufficiency: GFR <15 ml/min/1,73m2, dialysis or transplantation. 
Growth failure: defined as the presence of at least two of the three features:  
- lower than the 3rd percentile height for age 
- growth velocity over 6 months lower than the 3rd percentile for age 
- crossing at least 2 centiles (5%, 10%, 25%, 50%, 75%, 90%, 95%) on growth chart  
For patients older than 18 years: Pathological short stature (e.g. below 3rd percentile for normal ethnic 
population)  
Puberty delay: A Tanner stage below minus two standard deviations for age. 
Serosal scarring: Adhesions or fibrosis affecting pericardium, pleura, peritoneum and/or retroperitoneum, 
supported by imaging techniques, endoscopy or surgery. 
Developmental delay: Failure to reach age-appropriate developmental milestones, including 
language/speech, motor, social/emotional, and cognitive milestones. As soon as there is any delay in one of 
the development categories, this item has to be scored.1 
Cognitive impairment: Requirement of special education because of cognitive impairment or IQ below 70 as 
defined by neuropsychological assessment (e.g. WISC) or other age-appropriate equivalents.  
Elevated intracranial pressure: Signs and/or symptoms of elevated intracranial pressure supported by 
appropriate techniques. 2 
Central nervous system involvement: Focal deficits (gross and/or fine sensorimotor), diffuse deficits (e.g. 
memory, behaviour), seizures, and spinal cord symptoms.  
Moderate hearing loss: Sensorineural hearing impairment confirmed by audiometry or another age 
appropriate technique without requirement of hearing aids or a cochlear implant  
Severe hearing loss: Sensorineural hearing impairment confirmed by audiometry or another age appropriate 
technique requiring hearing aids or a cochlear implant. 
Mild ocular involvement: Ocular damage (e.g. optic nerve atrophy, elevated intraocular pressure or 
cataract) documented by an ophthalmologist, without visual impairment.  
Moderate ocular involvement: Ocular damage (e.g. optic nerve atrophy, elevated intraocular pressure or 
cataract) documented by an ophthalmologist, resulting in visual impairment.  
Severe ocular involvement: Ocular damage (e.g. optic nerve atrophy, elevated intraocular pressure or 
cataract) documented by an ophthalmologist, resulting in legal blindness. 
Joint restriction: Fixed limitation in the normal range of motion of joints, with or without destructive 
arthropathy or avascular necrosis. 
Bone deformity: Bone deformation or overgrowth on clinical examination and/or imaging studies.  
Osteoporosis: Reduced bone mineral density with vertebral collapse and/or pathological fractures 
confirmed with imaging, which may include bone densitometry. Requires both evidence of decreased bone 
density and fracture, ‘low bone density’ by itself is insufficient  
Musculoskeletal pain: Non-inflammatory musculoskeletal pain impairing activities of daily living. 
 
1 Only for paediatric patients. 2 Such as fundoscopy, neuroimaging or lumbar CSF pressure measurement. 
 
DISCUSSION 
We developed a damage index for AID. The proposed ADDI contains eighteen items. The damage 
items are categorized by organ system. All damage items are clearly defined and easy to score. 
Completing the ADDI should take approximately five minutes. The ADDI will make it possible to 
analyse outcomes in patient groups and compare the results of different studies, but also to 
systematically measure damage in a single patient. 
 
The first key strength in the development of the ADDI is the number of worldwide experts that 
participated. Forty European/Middle Eastern and nine American experts were invited, with the aim 
of making the ADDI a global instrument. We made the selection of experts based on their clinical 
experience, which guarantees the capability of these experts to judge the importance of damage 
caused by AID. Furthermore, all online surveys were completed by more than eighty percent of the 
experts, which is important for both validity and acceptability of consensus statements. A high 
proportion of the experts attended the consensus meeting. 
 
The second key strength is the participation of patients and parents of patients in all the steps that 
led to the development of the ADDI. This is important to make it a widely relevant damage index that 
can represent the burden for patients.  
 
The third key strength is the methodology used to select the possible damage items. We screened for 
possible damage items in three ways. It was evident from the literature search that studies of long-
term damage using a large sample size are extremely scarce in autoinflammatory diseases. The 
screening of items in the Eurofever registry, and suggestions of patients and experts were 
consequently valuable in developing a comprehensive set of items to asses in the online surveys. 
 
Although many new damage items were suggested by patients and parents of patients, it might be 
possible that the participating patients have not suggested all possible damage items and they may 
not reflect the opinion of the whole patient population. Nevertheless, their contribution strengthens 
the process and resulted in consideration of previously neglected damage items that had not been 
described in the literature nor mentioned by experts, for example chronic pain and chronic fatigue.  
FMF patients were underrepresented in this study, despite attempts to recruit more patients for the 
1000minds survey. Overall the amount of patients that signed informed consent as well as the 
response rate to surveys was lower than expected. Possible reasons might be the inclusion criterium 
for patients to be English speaking, the difficulty and length of the questionnaires and the informed 
consent procedure. 
 
We chose to develop a general damage index limited to the four most prevalent monogenetic AID: 
FMF, CAPS, TRAPS and MKD. Based on the literature the affected organ systems might differ in 
prevalence between these diseases, nevertheless the ADDI will be a good tool to structurally score 
damage and covers all the important damage items for these four diseases.  It would be challenging 
to develop the ADDI to capture damage in all AID, due to the expanding number of new ultra-rare 
autoinflammatory diseases, and their varied clinical features. An example of a recently discovered 
AID is the chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
(CANDLE) syndrome. While CANDLE does share some damage items with other AID, lipodystrophy is 
characteristic for CANDLE[121], but is uncommon in FMF, CAPS, TRAPS and MKD, illustrating the 
difficulty in developing a damage index applicable to all existing and yet to be discovered AID.  
 
Common nonspecific symptoms like chronic headache, fatigue and chronic musculoskeletal pain gave 
rise to intense discussions. Ultimately, only chronic musculoskeletal pain is included in the 
preliminary ADDI. Although patients considered these items as important in the surveys and 
interviews, experts thought that these items were difficult to assess objectively in daily clinical 
practice, and found it hard to define whether these items actually reflected disease damage, rather 
than on-going disease activity. Nonetheless experts acknowledged that these items have a 
considerable impact on the quality of life. In the future these items might be better included in a 
different tool, e.g. with specific items to measure quality of life.  
 
Another difficulty in the development of the ADDI was the influence of comorbidities on the damage 
in AID patients. This is a common issue for all damage indices. For example neurological impairment 
can be caused by the AID or by an unrelated stroke. It is very hard to distinguish whether it is caused 
by independent comorbidities or the disease itself, even though we only include damage items that 
arose after the onset of symptoms of the AID.  
 
In the near future, the preliminary ADDI will be validated using patient cases of FMF, CAPS, TRAPS 
and MKD. By this effort, we will be able to assess the validity of the ADDI in total, and for the 
individual diseases. Furthermore, we will analyse the specificity of the ADDI items (e.g. whether the 
damage items are not influenced by disease activity) and the grading system. Prospective validation 
in longitudinal cohorts will then be needed to investigate responsiveness to change over time and 
correlation with the burden of disease-associated damage to daily life. 
 
In conclusion, we developed the ADDI, a universal instrument to measure persisting damage caused 
by chronic inflammation in the autoinflammatory diseases FMF, CAPS, TRAPS and MKD. This ADDI is 
based on consensus building with experts from around the world; patients and parents of patients 
fulfilled a significant role in this process.  
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LEGENDS OF FIGURES 
Figure 1: damage items extracted from literature for FMF[3 19-71], CAPS[3 72-106], TRAPS[3 107-
113], and MKD[3 114-120]. 
 
Figure 2. Scoring of the preference values from experts (black) and patients (grey), derived from the 
1000minds decision making software. A higher preference value means a higher burden for patients. 
The preference values range from 1.5 to 7.5, all items with a weighted mean preference value of <3.5 
received one point in the ADDI, and of >5.5 three points. 
 
